Dasotraline
- Generic Name
- Dasotraline
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15Cl2N
- CAS Number
- 675126-05-3
- Unique Ingredient Identifier
- 4D28EY0L5T
- Background
Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, and Adult Attention Deficit Hyperactivity Disorder.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
- Conditions
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT03231800
- Locations
- ๐บ๐ธ
Avida Inc, Newport Beach, California, United States
๐บ๐ธQps-Mra, Llc, South Miami, Florida, United States
๐บ๐ธSouth Shore Psychiatric Services PC, Hingham, Massachusetts, United States
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02795637
- Locations
- ๐บ๐ธ
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
๐บ๐ธDaVita Clinical Research, Minneapolis, Minnesota, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States
Dasotraline Binge Eating Disorder Extension Study
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 533
- Registration Number
- NCT02684279
- Locations
- ๐บ๐ธ
Neuotrials Research, Inc., Atlanta, Georgia, United States
๐บ๐ธBoston Clinical Trials, Boston, Massachusetts, United States
๐บ๐ธTexas Center for Drug Development, Inc., Houston, Texas, United States
Dasotraline Binge Eating Disorder Study
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 319
- Registration Number
- NCT02564588
- Locations
- ๐บ๐ธ
PCSD- Feighner Research, San Diego, California, United States
๐บ๐ธCapstone Clinical Research, Libertyville, Illinois, United States
๐บ๐ธSunstone Medical Research, LLC, Medford, Oregon, United States
Dasotraline Pediatric Extension Study
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT02457819
- Locations
- ๐บ๐ธ
Psychiatric Associates, Overland Park, Kansas, United States
๐บ๐ธHarmonex Neuroscience Research, Inc, Dothan, Alabama, United States
๐บ๐ธClinical Trials group at the Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States
Dasotraline Pediatric ADHD Study
- Conditions
- Interventions
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT02428088
- Locations
- ๐บ๐ธ
Gulfcoast Clinical Research, Fort Myers, Florida, United States
๐บ๐ธNeurobehaviorial Medicine Group, PLLC, Bloomfield Hills, Michigan, United States
๐บ๐ธHarmonex Neuroscience Research, Dothan, Alabama, United States
Dasotraline Adult ADHD Study
- Conditions
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 636
- Registration Number
- NCT02276209
- Locations
- ๐บ๐ธ
Gulfcoast Clinical Research, Fort Myers, Florida, United States
๐บ๐ธKennedy Krieger Institute, Baltimore, Maryland, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
Open-label Safety Study in Adults With ADHD
- Conditions
- Interventions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 724
- Registration Number
- NCT02160262
- Locations
- ๐บ๐ธ
Premeir Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States
๐บ๐ธPillar Clinical Research, LLC, Dallas, Texas, United States
๐บ๐ธFamily Psychiatry of the Woodlands, The Woodlands, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.